[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340509-105":59,"doc-detail-340509-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","advancements-in-p53-based-anti-tumor-gene-therapy-research","Advancements in p53-Based Anti-Tumor Gene Therapy Research","","The p53 gene is tightly linked to human tumors and serves as a frequent target in anti-cancer drug design. Although p53-based gene therapy has advanced, practical use is constrained by incomplete technology maturity, safety risks, limited clinical efficacy, and variable patient acceptance. This review surveys key developments in p53-based gene therapy and related nucleic-acid delivery technologies, and outlines future prospects to support continued progress in the field.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/advancements-in-p53-based-anti-tumor-gene-therapy-research/340509/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/advancements-in-p53-based-anti-tumor-gene-therapy-research/340509.png","ImageObject",300,407,{"name":92,"@type":93},"Evangeline","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":81},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is p53 considered a major target in anti-tumor therapy?","Question",{"text":112,"@type":113},"p53 is closely associated with human tumors and plays a central role in regulating responses such as cell cycle arrest, senescence, apoptosis, DNA repair, and other tumor-related processes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What problems limit the clinical adoption of p53-based gene therapy?",{"text":117,"@type":113},"Current p53-based approaches face challenges including insufficient technical maturity, high safety hazards, limited efficacy, and relatively low patient acceptance.",{"name":119,"@type":110,"acceptedAnswer":120},"How does gene therapy address faulty genes involved in cancer?",{"text":121,"@type":113},"Gene therapy aims to deliver therapeutic genes into specific cells to compensate for defective genes, mute harmful genes, or correct abnormal genes, leveraging the genetic basis of cancer.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340509,1792193046,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":81,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","Review  \nAdvancements in p53-Based Anti-Tumor Gene Therapy Research  \nYuanwan Peng 1, Jinping Bai 1, Wang Li 1, Zhengding Su 2, * and Xiyao Cheng 1, *  \nCitation: Peng, Y.; Bai, J.; Li, W.; Su, Z.; Cheng, X. Advancements in p53-Based Anti-Tumor Gene Therapy Research. Molecules 2024, 29, 5315. [https://](https://)[ ](https://)[doi.org/10.3390/molecules29225315](doi.org/10.3390/molecules29225315)  \nReceived: 14 October 2024  \nRevised: 5 November 2024  \nAccepted: 7 November 2024  \nPublished: 11 November 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Institute of Modern Fermentation Engineering and Future Foods, School of Light Industry and Food Engineering, Guangxi University, No. 100, Daxuedong Road, Nanning 530004, China; [2216394003@st.gxu.edu.cn](2216394003@st.gxu.edu.cn) (Y.P.); [2316392001@st.gxu.edu.cn](2316392001@st.gxu.edu.cn) (J.B.); [2416393006@st.gxu.edu.cn](2416393006@st.gxu.edu.cn) (W.L.)  \n2 School of Pharmaceutical Sciences and Institute of Materia Medica, Xinjiang University, Urumqi 830017, China * [Correspondence: james_su@xju.edu.cn](Correspondence: james_su@xju.edu.cn) (Z.S.); [xiyaocheng@gxu.edu.cn](xiyaocheng@gxu.edu.cn) (X.C.)  \nAbstract: The p53 gene is one of the genes most closely associated with human tumors and has become a popular target for tumor drug design. Currently, p53-based gene therapy techniques have been developed, but these therapies face challenges such as immaturity, high safety hazards, limited efficacy, and low patient acceptance. However, researchers are no less enthusiastic about the treatment because of its theoretical potential to treat cancer. In this paper, the advances in p53-based gene therapy and related nucleic acid delivery technologies were reviewed and prospected in order to support further development in this field.  \nKeywords: p53; gene therapy; tumor; delivery vector  \n1. Introduction  \nThe p53 gene plays a crucial role in inhibiting tumors in humans and is the gene most closely associated with human tumors identified to date. In stress-free cells, the wild-type p53 (WTp53) protein encoded by the WTp53 gene exists mainly in dimer form. When cells are exposed to stress signals such as hypoxia, DNA damage, and oxidative stress, the WTp53 protein is activated through phosphorylation and acetylation pathways and then assembled into tetramers. The WTp53 tetramer identifies p53 binding sites located in the promoter or enhancer of target genes through their DNA binding domain to regulate transcription, triggering cell cycle arrest [1], senescence [2,3], apoptosis [4,5], DNA repair [1], ferroptosis [6], autophagy [7–9], tumor angiogenesis inhibition [10–12], and other functions. P53 is not only a transcription factor that executes the signal but also interacts with other proteins in the cell to execute the signal. P53 in cytoplasm is also involved in regulating cellular metabolic activities, such as glycolysis [13] . In addition, p53 affects immune system function. WTp53 makes tumor cells more susceptible to immune cell attacks [14], whereas the absence of WTp53 in tumor cells limits immune system attacks on cancer cells [15] .  \nHowever, p53 gene mutations occur in over 50% of human tumors, and the mutant p53 (MTp53) gene may lose its anti-cancer activity or even become oncogenic [16,17] . Cancerous cells devoid of WTp53 are capable of enduring genomic instability and amplified cancercausing signals, and the advancement of cancer is markedly hastened when the p53 gene is missing or altered [18] . Even when tumor cells carry WTp53, the anti-cancer activity of WTp53 may be reduced due to the overexpression of Mdm2 and MdmX [19,20] . Given the strong link between p","cbCaivfI7s0zP06G","https://ap.wps.com/l/cbCaivfI7s0zP06G","pdf",2222279,26,"English","# Introduction\n## p53 structure and tumor suppressor functions\n## Cancer relevance of mutant p53\n## Rationale for p53 targeting in anti-cancer therapy\n## Fundamentals and advantages of gene therapy\n## p53 regulation via Mdm2/MdmX","[{\"question\":\"Why is p53 considered a major target in anti-tumor therapy?\",\"answer\":\"p53 is closely associated with human tumors and plays a central role in regulating responses such as cell cycle arrest, senescence, apoptosis, DNA repair, and other tumor-related processes.\"},{\"question\":\"What problems limit the clinical adoption of p53-based gene therapy?\",\"answer\":\"Current p53-based approaches face challenges including insufficient technical maturity, high safety hazards, limited efficacy, and relatively low patient acceptance.\"},{\"question\":\"How does gene therapy address faulty genes involved in cancer?\",\"answer\":\"Gene therapy aims to deliver therapeutic genes into specific cells to compensate for defective genes, mute harmful genes, or correct abnormal genes, leveraging the genetic basis of cancer.\"}]","Advancements in p53-Based Anti-Tumor Gene Therapy Research | PDF",1790036946,66,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ecb5d29d0d45cc0ef78e2dab3f665b7f.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d1cff837c3c74b31f8895a2594c49d9c.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7f4f0eb53a5019bf8b200c79c0eb9205.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/030d7e1eba27f1d179ea7f4a4e58c847.webp",980,1385]